<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01121172</url>
  </required_header>
  <id_info>
    <org_study_id>10012010</org_study_id>
    <nct_id>NCT01121172</nct_id>
  </id_info>
  <brief_title>Apelin Levels and G212A Polymorphism of Apelin Receptor (APJ)</brief_title>
  <official_title>Serum Apelin Levels and G212A Polymorphism of Apelin Receptor (APJ)in Obese Children and Adolescents.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aristotle University Of Thessaloniki</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aristotle University Of Thessaloniki</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate serum apelin levels as well as their possible
      association with G212A polymorphism of the apelin receptor in obese children and adolescents.

      So far apelin has been reported to be involved in the pathophysiology of various heart
      diseases such as cardiomyopathies and heart failure. According to recent reports in adults
      apelin seems to be associated with impaired glucose metabolism, particularly in newly
      diagnosed diabetes type 2 patients. Obesity is associated with insulin resistance and
      compensatory hyperinsulinemia leading to diabetes mellitus type 2 even in youngsters. The
      researchers will try to investigate the role of this new adipokine in order to early detect
      and to prevent similar entities in childhood obesity.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Serum Apelin Levels</measure>
    <time_frame>First day after enrollment and after 8-hours of night fasting, at approximately 8:00 pm in the morning</time_frame>
    <description>Apelin levels were measured in serum of participants, in fasting state</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of G212A Polymorphism of Apelin Receptor in Obese Children and Adolescents</measure>
    <time_frame>First day after enrollment</time_frame>
    <description>Number of participants with Apelin Receptor Gene G212A polymorphism by genotype group</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">180</enrollment>
  <condition>Obesity</condition>
  <condition>Insulin Resistance</condition>
  <condition>Diabetes Mellitus Type 2</condition>
  <arm_group>
    <arm_group_label>obese</arm_group_label>
    <description>obese subjects according to International Obesity Task Force criteria</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lean</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        40 obese children 40 obese adolescents 50 lean children 50 lean adolescents
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Obese children and adolescents (aged 2-16 years old)

        Exclusion Criteria:

          -  Chronic diseases

          -  Hypothyroidism

          -  Medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Unit of Pediatric Endocrinology, Diabetes and Metabolism-4th Department of Pediatrics, Medical School of Aristotle University of Thessaloniki</name>
      <address>
        <city>Thessaloniki</city>
        <zip>56403</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2010</study_first_submitted>
  <study_first_submitted_qc>May 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2010</study_first_posted>
  <results_first_submitted>March 15, 2016</results_first_submitted>
  <results_first_submitted_qc>April 13, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 19, 2016</results_first_posted>
  <last_update_submitted>April 13, 2016</last_update_submitted>
  <last_update_submitted_qc>April 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aristotle University Of Thessaloniki</investigator_affiliation>
    <investigator_full_name>Assimina Galli-Tsinopoulou</investigator_full_name>
    <investigator_title>As. Professor in Pediatric Endocrinology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Obese</title>
          <description>obese children and adolescents according to International Obesity Task Force criteria</description>
        </group>
        <group group_id="P2">
          <title>Lean</title>
          <description>lean children and adolescents matched for age and gender to the obese group</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="90"/>
                <participants group_id="P2" count="90"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="90"/>
                <participants group_id="P2" count="90"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Obese</title>
          <description>obese children and adolescents according to International Obesity Task Force criteria</description>
        </group>
        <group group_id="B2">
          <title>Lean</title>
          <description>lean children and adolescents matched for age and gender to the obese group</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="90"/>
            <count group_id="B2" value="90"/>
            <count group_id="B3" value="180"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.6" lower_limit="2.6" upper_limit="16.5"/>
                    <measurement group_id="B2" value="11.7" lower_limit="3.3" upper_limit="17.8"/>
                    <measurement group_id="B3" value="11.6" lower_limit="2.6" upper_limit="17.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Greece</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Serum Apelin Levels</title>
        <description>Apelin levels were measured in serum of participants, in fasting state</description>
        <time_frame>First day after enrollment and after 8-hours of night fasting, at approximately 8:00 pm in the morning</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Obese</title>
            <description>obese children and adolescents according to International Obesity Task Force criteria</description>
          </group>
          <group group_id="O2">
            <title>Lean</title>
            <description>lean children and adolescents matched for age and gender to the obese group</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Apelin Levels</title>
          <description>Apelin levels were measured in serum of participants, in fasting state</description>
          <units>ng/ml</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.45" lower_limit="0.63" upper_limit="4.54"/>
                    <measurement group_id="O2" value="1.91" lower_limit="0.55" upper_limit="4.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>Non parametric test</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of G212A Polymorphism of Apelin Receptor in Obese Children and Adolescents</title>
        <description>Number of participants with Apelin Receptor Gene G212A polymorphism by genotype group</description>
        <time_frame>First day after enrollment</time_frame>
        <population>Data were collected only from the Obese participants. Data regarding the genetic polymorphism were not collected from participants forming the Lean Arm/Group.</population>
        <group_list>
          <group group_id="O1">
            <title>Obese Group</title>
            <description>Obese children and adolescents according to IOTF criteria</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of G212A Polymorphism of Apelin Receptor in Obese Children and Adolescents</title>
          <description>Number of participants with Apelin Receptor Gene G212A polymorphism by genotype group</description>
          <population>Data were collected only from the Obese participants. Data regarding the genetic polymorphism were not collected from participants forming the Lean Arm/Group.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.232</p_value>
            <method>Chi-squared</method>
            <method_desc>Chi-square test of frequency distribution amng obese study group and HapMap-CEU polymorphism distribution</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>This is a cross-sectional non intervantional, observation study. Time for reporting adverse events was the first day after enrollment, during which blood samples were collected.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Obese</title>
          <description>obese children and adolescents according to International Obesity Task Force criteria</description>
        </group>
        <group group_id="E2">
          <title>Lean</title>
          <description>lean children and adolescents matched for age and gender to the obese group</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Assimina Galli-Tsinopoulou, As.Professor of Pediatric Endocrinology</name_or_title>
      <organization>4th Department of Pediatrics, School of Medicine, Aristotle University of Thessaloniki</organization>
      <phone>00302310991537</phone>
      <email>agalli@auth.gr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

